Trial Profile
A Phase II, Pharmacokinetic, Randomized, Double-Masked, Controlled, Dose Comparison Study of Cand5 for Intraviteral Injection for the Treatment of Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2014
Price :
$35
*
At a glance
- Drugs Bevasiranib (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Sponsors OPKO Health
- 25 Oct 2006 New trial record.